Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs. Issue 3 (12th September 2013)

• Record Type: Journal Article
• Authors: Boada, Mercè; Tárraga, Lluís; Hernández, Isabel; Valero, Sergi; Alegret, Montserrat; Ruiz, Agustín; Lopez, Oscar L.; Becker, James T.
• Is Part Of: Alzheimer's & dementia. Volume 10:Issue 3(2014)
• Page Start: 409
• Page End: 415
• Publication Date: 2013-09-12
• Subjects: Dementia -- Alzheimer's disease -- Spain -- Natural history; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2013.03.006
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Objectives: Alzheimer's disease (AD) affects people worldwide, and the prevalence is increasing as the population ages. There is an international effort to understand the biology of AD to develop primary and secondary prevention strategies, and to develop effective therapeutic interventions for individuals who are already symptomatic. One of the critically important pieces of all national plans to address AD is the call for the development of service models to deliver quality, effective care based on the best evidence available. Methods: We describe one type of care model developed by the Fundacio ACE, Institut Catala de Neurociencies Aplicades (Fundacio ACE, Barcelona, Spain) that integrates diagnosis, therapy, follow‐up care, daycare, and a day hospital, and does so in the context of an active clinical research and educational program. Results: There were 13, 048 individuals newly evaluated and diagnosed in Fundacio ACE between 1996 and 2011. Of these, 6132 had AD (47.0%), 3871 had mild cognitive impairment (MCI) (29.7%), and 1958 had no cognitive impairment (15.0%). Follow‐up information is available on 4735 (47.3%) AD and MCI patients, and these data indicate that MCI develops into dementia at a rate of 222.6/1000 person‐years. Apolipoprotein E (APOE) genotyping was available in 22.4% of the patients. The ε4 allele occurred in 45.7% of the AD patients, in 37.8% of the MCI subjects, and in 31.6% of those without cognitive impairment. Conclusions: Fundació ACE can serve as a model system that can be adapted to other settings within their specific cultural, governmental, and legal constraints.